ARADIGM CORP Contracts & Agreements
78 Contracts & Agreements
- Business Finance (26 contracts)
- Business Operations (7)
- Human Resources (12)
- Intellectual Property (1)
- Real Estate (1)
- Uncategorized (31)
- Bidding Procedures (Filed With SEC on March 9, 2020)
- Asset Purchase Agreement dated February 18, 2020, between Aradigm Corporation and Grifols, S.A (Filed With SEC on February 21, 2020)
- Form of 9.0% Convertible Senior Notes due 2021 (Filed With SEC on November 6, 2018)
- Change of Control Agreement between Aradigm Corporation and John Siebert, dated as of October 31, 2018 (Filed With SEC on November 1, 2018)
- Senior Note Purchase Agreement, dated October 25, 2018, by and between Aradigm Corporation and Grifols Worldwide Operations Ltd (Filed With SEC on October 30, 2018)
- Form of 9.0% Senior Promissory Note due 2021 (Filed With SEC on October 30, 2018)
- Aradigm Corporation Employee Stock Purchase Plan, as amended (Filed With SEC on August 14, 2018)
- Employment Agreement between Aradigm Corporation and Juergen Froehlich, dated May 31, 2018 (Filed With SEC on June 6, 2018)
- Change of Control Agreement between Aradigm Corporation and Juergen Froehlich, dated May 31, 2018 (Filed With SEC on June 6, 2018)
- Form of 9.0% Convertible Senior Notes due 2021 (Filed With SEC on May 7, 2018)
- Supplemental Indenture, dated as of April 18, 2018, between the Company and U.S Bank National Association, as trustee (Filed With SEC on April 23, 2018)
- Senior Note Purchase Agreement, dated April 13, 2018, among Aradigm Corporation, Grifols Worldwide Operations Ltd., 21 April Fund, Ltd., 21 April Fund, LP and First Eagle Value in... (Filed With SEC on April 18, 2018)
- Form of 9.0% Senior Promissory Note due 2021 (Filed With SEC on April 18, 2018)
- Employment Agreement between Aradigm Corporation and John Siebert, March 22, 2018 (Filed With SEC on March 28, 2018)
- SECURITIES PURCHASE AGREEMENT by and between ARADIGMCORPORATION and THE PURCHASERS NAMED ON SCHEDULES A and B HERETO Dated as of April 21, 2016 Table of Contents (Filed With SEC on April 28, 2016)
- ARADIGM CORPORATION AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of April 25, 2016 9.0% Convertible Senior Notes due 2021 TABLE OF CONTENTS (Filed With SEC on April 28, 2016)
- ESCROW AGREEMENT (Filed With SEC on April 28, 2016)
- AMENDMENT TO GOVERNANCEAGREEMENT (Filed With SEC on April 28, 2016)
- AMENDMENT TO THE STOCK OPTION AGREEMENT (Filed With SEC on March 30, 2016)
- SUPPLY AGREEMENT (Filed With SEC on March 30, 2016)
- ARADIGM CORPORATION STOCK OPTION AGREEMENT (Filed With SEC on March 13, 2014)
- ASSIGNMENT, ASSUMPTION, WAIVER AND CONSENT February 28, 2014 (Filed With SEC on March 10, 2014)
- CHANGE OF CONTROL AGREEMENT (Filed With SEC on February 4, 2014)
- ATTACHMENT A (Filed With SEC on February 4, 2014)
- CLINICAL SUPPLY AND COMMERCIAL MANUFACTURING SERVICES AGREEMENT (Filed With SEC on October 28, 2013)
- STOCK PURCHASE AGREEMENT by and between ARADIGM CORPORATION and GRIFOLS, S.A. Dated as of May 20, 2013 TABLE OF CONTENTS (Filed With SEC on May 24, 2013)
- LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on May 24, 2013)
- Aradigm-Grifols Option Terms for License, Development andCommercialization Agreement for Use of AERx Inhaler with Alpha-1 Antitrypsin Background (Filed With SEC on May 24, 2013)
- GOVERNANCE AGREEMENT by and between ARADIGM CORPORATION and GRIFOLS, S.A. Dated as of [ ], 2013 TABLE OF CONTENTS (Filed With SEC on May 24, 2013)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on May 24, 2013)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on May 24, 2013)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on December 13, 2012)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on December 13, 2012)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on July 6, 2011)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on July 6, 2011)
- ARADIGM CORPORATION EXECUTIVE OFFICER SEVERANCE BENEFIT PLAN (Filed With SEC on April 18, 2011)
- AMENDED AND RESTATED CHANGE OF CONTROL AGREEMENT (Filed With SEC on April 18, 2011)
- Signature Page to Amended and Restated Change of Control Agreement (Filed With SEC on April 18, 2011)
- ARADIGM CORPORATION (Filed With SEC on April 18, 2011)
- FINANCIAL STATEMENTS (Filed With SEC on November 6, 2009)
- FINANCIAL STATEMENTS (Filed With SEC on November 6, 2009)
- FINANCIAL STATEMENTS (Filed With SEC on November 6, 2009)
- FINANCIAL STATEMENTS (Filed With SEC on November 6, 2009)
- ARADIGM CORPORATION Employee Stock Purchase Plan Adopted April 16, 1996 Approved by the Shareholders on June 5, 1996 Amended by the Board of Directors on April 7, 1998 Approved by... (Filed With SEC on May 21, 2009)
- 4,000,000 Shares (Filed With SEC on February 26, 2009)
- 40,663,071 Shares (Filed With SEC on February 24, 2009)
- ARADIGM CORPORATION EXECUTIVE OFFICER SEVERANCE BENEFIT PLAN (Filed With SEC on January 8, 2009)
- CHANGE OF CONTROL AGREEMENT (Filed With SEC on January 8, 2009)
- ARADIGM CORPORATION CONSULTING AGREEMENT FOR INDEPENDENT CONTRACTORS (Filed With SEC on December 19, 2008)
- Aradigm Corporation International Scientific Advisory Agreement (Filed With SEC on December 19, 2008)
- Current assets (Filed With SEC on November 12, 2008)
- Current assets (Filed With SEC on August 8, 2008)
- Current assets (Filed With SEC on August 8, 2008)
- Current assets (Filed With SEC on November 14, 2007)
- Current assets (Filed With SEC on November 14, 2007)
- MASTER DEVELOPMENT AND MANUFACTURING AGREEMENT Clinical Products (Filed With SEC on August 14, 2007)
- SUBLEASE (Filed With SEC on July 24, 2007)
- Consulting Agreement effective as of July 2, 2007 by and between the Company and Norman Halleen (Filed With SEC on July 11, 2007)
- AMENDMENT NO. 3 TO RIGHTS AGREEMENT BETWEEN ARADIGM CORPORATION AND COMPUTERSHARE TRUST COMPANY, N.A. (Filed With SEC on January 30, 2007)
- We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior... (Filed With SEC on January 4, 2007)
- We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior... (Filed With SEC on January 4, 2007)
- We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior... (Filed With SEC on October 24, 2006)
- We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior... (Filed With SEC on October 24, 2006)
- We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior... (Filed With SEC on October 24, 2006)
- We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior... (Filed With SEC on October 24, 2006)
- We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior... (Filed With SEC on October 24, 2006)
- We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior... (Filed With SEC on October 24, 2006)
- Current assets (Filed With SEC on August 14, 2006)
- Stage of Development (Filed With SEC on March 31, 2006)
- Stage of Development (Filed With SEC on March 31, 2006)
- Securities Purchase Agreement, dated as of December 17, 2004 (Filed With SEC on December 23, 2004)
- In thousands, except shares data (Filed With SEC on November 15, 2004)
- ARADIGM CORPORATION SECURITIES PURCHASE AGREEMENT (Filed With SEC on November 20, 2003)
- ARADIGM CORPORATION SECURITIES PURCHASE AGREEMENT NOVEMBER 7, 2003 ARADIGM CORPORATION SECURITIES PURCHASE AGREEMENT (Filed With SEC on November 12, 2003)
- EXHBIIT 10.15A (Filed With SEC on March 29, 2002)
- EXHIBIT 10.15B (Filed With SEC on March 29, 2002)
- Novo Nordisk A/S, the world leader in insulin products, for the needle-free delivery of insulin for diabetes; and (Filed With SEC on March 29, 2002)
- Novo Nordisk A/S, the world leader in insulin products, for the needle-free delivery of insulin for diabetes; and (Filed With SEC on March 29, 2002)